Biotech Values

[rfj1862]

My 15-minute take on your list. Left out a few that are too obvious (like VLTS).

I wouldn't buy any of them, but if I had to, I'd buy NBIX or AVNR.

COR
Someone else can comment on this one. I’ll keep my mouth shut.

CORT
Absolutely hopeless. RU486 has no effect on psychotic depression, and the company doesn’t have anything in the pipeline.

DOVP
I don’t know much about DOVP, and their website is confusing as hell. No idea here if the pain drug is promising or not.

ICGN
No hope here either since hydroxyurea failed. Although they have several drugs and leads in preclinical development, it’s going to be a long, long time before this moves.

INHX
DOA, since Veronate, their drug for prevention of staph infections in very-low-birth weight infants, is a mechanistic failure. Can’t believe this one every made it past the concept stage.

NBIX
The dust might have settled sufficiently to pick this one up. As of third quarter they had 404 million, or about 4 years at the current burn. They have a bunch of stuff in the pipeline (GnRH antagonist, urocortin for CHF, and an SNRI for neuropathic pain).

NEOL
Dead. Their glioblastoma drug is a complete failure, and the next best thing they have—“me too” liposome entrapped paclitaxel-- is just entering phase II.

NTMD
Don’t know enough about BiDil to have an opinion.

OCCX
Isn’t this the rheopheresis company that Cramer pumped? This will never go anywhere—in order to make any money, any treatment based on apheresis has to show outstanding efficacy given the cost and time involved in the treatments. This won’t.

RNVS
Dead. But they’ve got lots of cash. Maybe POTP should “merge” with them.

THLD
Gone. Does anyone really think glufosfamide is going to show efficacy in pancreatic cancer?